Search  Follow Investorideas on Twitter  Investorideas is on Facebook  Investorideas is on Google Plus  Investorideas is on Youtube  Investorideas is on Pinterest  Investorideas is on tumblr  Investorideas is on LinkedIn  Investorideas RSS 




HIV Vaccine Clinical Study Results in High Immune Response Rates in Healthy Subjects

Source: The Life Sciences Report

 

June 1, 2017 (Investorideas.com Newswire) A clinical study of an HIV vaccine in healthy subjects that found a nearly 100% immune response rate was hailed by a pair of industry analysts.


Inovio Pharmaceuticals Inc. (INO:NASDAQ) announced on May 24 that its HIV vaccine, PENNVAX-GP, produced among the "highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine." According to the company, "the vaccine candidate, PENNVAX-GP, consists of a combination of four HIV antigens designed to cover multiple global HIV strains and generate both an antibody (humoral) immune response as well as a T cell (cellular) immune response to both potentially prevent and treat HIV."

The company reported that "amongst the evaluated participants receiving PENNVAX-GP and IL-12 via IM vaccination, 27 of 27 (100%) demonstrated a cellular response and 19 of 21 (90%) demonstrated an env specific antibody response. Similar immune responses and response rates were achieved via both ID and IM administration of the vaccine although participants vaccinated via intradermal vaccine administration received 1/5th the dose of vaccine compared to those vaccinated via intramuscular administration."

Analyst Raghuram Selvaraju of H.C. Wainwright & Co., in a May 25 report, wrote that these "early results are very encouraging but not surprising, as they are in line with results from the company's trials of other DNA vaccines, including Ebola, Zika and MERS. Interestingly, the intradermal delivery utilized only 20% of the vaccine dose compared to intramuscular administration, yet achieved similar immune responses and response rates. We believe further studies would be conducted to determine whether PENNVAX-GP can safely and effectively prevent HIV infection."

Selvaraju reiterated the firm's Buy rating and $13 target price.

In a May 24 Maxim Group report, Jason McCarthy and Jason Kolbert wrote that "when PENNVAX-GP was combined with IL-12 the percent of patients showing both T cell and antibody responses was 100%, or near 100%. . .inducing both T cells to clear viral infected cells and antibodies to clear virus in the blood is key for an HIV vaccine, and where other vaccines fall short (inducing either one or the other)."

The analysts concluded that the "immune responses demonstrated by PENNVAX-GP are among the highest responses shown for an HIV vaccine. With this data, Inovio now has a more clear path forward in the HIV space and the stage is set for a larger clinical program. In addition, we are focused on the VGX-3100 program and the start of the P3 program in cervical dysplasia, which we expect in mid-2017."

Maxim has a Buy rating on Inovio and raised its 12-month target price to $12 from $10. The company's shares are trading at around $7.55.

The Motley Fool, in an article by George Budwell dated May 24, noted that an "effective and safe HIV vaccine that can prevent and/or cure patients would easily generate billions in sales in short order. As proof, Gilead Sciences Inc. (GILD:NASDAQ), the market share leader in terms of HIV drug sales, rakes in around $13 billion annually for its HIV product line. If Inovio can capture even a sliver of this multi-billion-dollar market, it would be a ginormous win for shareholders, especially in light of the company's present market cap of only $657 million."

Read what other experts are saying about:

Disclosure:

1) Patrice Fusillo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She or members of her household own shares of the following companies mentioned in this article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) Inovio Pharmaceuticals Inc. is a sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks


More Info:

Investorideas.com Newswire

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Questrade Democratic Pricing - 1 cent per share, $4.95 min / $9.95 max



Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner